Scoop: Med­Im­mune chief Bahi­ja Jal­lal is leav­ing As­traZeneca and join­ing the trek in­to biotech

Six years af­ter As­traZeneca’s then new CEO Pas­cal So­ri­ot named Bahi­ja Jal­lal pres­i­dent of the big Med­Im­mune sub­sidiary in Gaithers­burg, MD, putting her at the cen­ter of the com­pa­ny’s R&D turn­around plans, the long­time phar­ma ex­ec is join­ing the great mi­gra­tion of in­dus­try pro­fes­sion­als to biotech.

Eliot Forster

Jal­lal is tak­ing the helm at Im­muno­core next week, a promi­nent TCR play­er in the UK which has been go­ing through a re­mark­able shake­up af­ter the orig­i­nal team un­der CEO Eliot Forster — now chief at F-star — ei­ther left or were forced out. Im­muno­core was able to raise $320 mil­lion a lit­tle more than 3 years ago — a time when that kind of mon­ey was still able to cause as­ton­ish­ment in the in­dus­try.

This wasn’t the first such biotech job to come along, Jal­lal tells me in an ex­clu­sive in­ter­view ahead of the an­nounce­ment. “But when the right one is there you jump on it.”

The job starts on Mon­day, and Jal­lal says she feels like “a kid in a can­dy store” when it comes to Im­muno­core, a com­pa­ny with a broad plat­form that is built to ac­com­mo­date on­col­o­gy as well as in­fec­tious dis­eases and au­toim­mune con­di­tions.

And Jal­lal isn’t the on­ly se­nior As­traZeneca ex­ec head­ing to new biotech fields. The Wall Street Jour­nal re­ports to­day that Mark Mal­lon — cur­rent EVP in charge of port­fo­lio strat­e­gy — is on his way to take the CEO job at Iron­wood, as that com­pa­ny splits up un­der pres­sure and Pe­ter Hecht leaves to run the R&D spin­out.

An­drew Hotchkiss

Over the past year-plus Im­muno­core has run in­to some se­vere tur­bu­lence af­ter it tried to shop a new round at its old uni­corn val­u­a­tion. Po­ten­tial in­vestors weren’t ready to buy in, trig­ger­ing an ex­o­dus at the top and a move up for chief com­mer­cial of­fi­cer An­drew Hotchkiss as in­ter­im chief.

Jal­lal says Hotchkiss has done a great job this year, which in­cludes ink­ing a ma­jor new pact with Genen­tech, and he’ll go back to con­cen­trat­ing on his com­mer­cial fo­cus with an eye on ad­vanc­ing Im­muno­core’s late-stage can­cer ther­a­py to­ward the mar­ket.

“I can tell you there’s been a lot of progress in the past year,” she adds. “Next week we’re go­ing to JP­Mor­gan and share the sto­ry with the in­vestor com­mu­ni­ty and oth­ers. My in­ten­tion is to bring re­as­sur­ance to in­vestors that I will bring sta­bil­i­ty to the or­ga­ni­za­tion, bring the best team and have the vi­sion we can all work to­geth­er and show them why I am join­ing the com­pa­ny.”

Mene Pan­ga­los

Jal­lal was one of three top R&D ex­ecs So­ri­ot picked for the Big Phar­ma’s turn­around in 2013. Brig­gs Mor­ri­son left sev­er­al years ago to run Syn­dax. That leaves Mene Pan­ga­los and his new col­leagues to run the show at As­traZeneca’s re­search and de­vel­op­ment op­er­a­tions.

There’s no im­me­di­ate word on who will re­place Jal­lal at Med­im­mune, where she steered 5 drugs to an ap­proval, in­clud­ing their check­point play­er Imfinzi.


Im­age: Bahi­ja Jal­lal. MED­IM­MUNE

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.